G1 Therapeutics (GTHX) Price Target Increased to $76.00 by Analysts at Needham & Company LLC
G1 Therapeutics (NASDAQ:GTHX) had its target price lifted by Needham & Company LLC to $76.00 in a research report report published on Tuesday morning, The Fly reports. The brokerage currently has a buy rating on the stock.
Several other brokerages have also issued reports on GTHX. HC Wainwright reissued a buy rating and issued a $79.00 target price on shares of G1 Therapeutics in a research report on Monday. BTIG Research began coverage on G1 Therapeutics in a research report on Monday, September 10th. They issued a buy rating and a $80.00 target price for the company. Cowen reissued a buy rating on shares of G1 Therapeutics in a research report on Thursday, August 9th. JPMorgan Chase & Co. increased their target price on G1 Therapeutics from $58.00 to $63.00 and gave the stock an overweight rating in a research report on Friday, August 10th. Finally, BidaskClub raised G1 Therapeutics from a buy rating to a strong-buy rating in a research report on Thursday, August 2nd. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $74.50.
Shares of NASDAQ:GTHX opened at $62.94 on Tuesday. G1 Therapeutics has a 52-week low of $18.03 and a 52-week high of $69.57. The company has a market capitalization of $2.27 billion, a PE ratio of -18.04 and a beta of -1.36.
In related news, VP Jennifer K. Moses sold 750 shares of the firm’s stock in a transaction that occurred on Thursday, July 5th. The stock was sold at an average price of $45.66, for a total transaction of $34,245.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Terry L. Murdock sold 3,519 shares of the firm’s stock in a transaction that occurred on Friday, August 3rd. The shares were sold at an average price of $50.60, for a total value of $178,061.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 49,288 shares of company stock valued at $2,698,269. 15.92% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of GTHX. Great West Life Assurance Co. Can boosted its stake in G1 Therapeutics by 148.3% during the 2nd quarter. Great West Life Assurance Co. Can now owns 2,612 shares of the company’s stock valued at $113,000 after purchasing an additional 1,560 shares during the last quarter. Cubist Systematic Strategies LLC boosted its stake in G1 Therapeutics by 484.5% during the 1st quarter. Cubist Systematic Strategies LLC now owns 2,794 shares of the company’s stock valued at $104,000 after purchasing an additional 2,316 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in G1 Therapeutics by 58.4% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,835 shares of the company’s stock valued at $105,000 after purchasing an additional 1,045 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in G1 Therapeutics by 44.4% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,900 shares of the company’s stock valued at $144,000 after purchasing an additional 1,200 shares during the last quarter. Finally, Strs Ohio boosted its stake in G1 Therapeutics by 78.3% during the 2nd quarter. Strs Ohio now owns 4,100 shares of the company’s stock valued at $178,000 after purchasing an additional 1,800 shares during the last quarter. 69.18% of the stock is owned by institutional investors.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
See Also: Google Finance Portfolio Workaround
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.